

BioNovelus Inc. Welcomes New Board of Directors and New Executive

2015-09-01 13:09 ET - News Release

(via Thenewswire.ca)

Scottsdale , Arizona / TheNewswire / September 1, 2015 - BioNovelus, Inc. (OTC: ONOV) , is pleased to announced the new Board of Directors, and the arrival in its team of Senior Executives in the Water Treatment Industry.

Effective immediately, BioNovelus Inc. has a new board of Directors. These Directors are passionate about the three pillars of sustainability: people, planet, and profit.

Board of Directors

The new board of directors will consist of:

Jean Ekobo, President

Richard Hess, Secretary

Marvin R. Clark, Treasurer

Frederick Taylor, Director

Iain Glass, Director

Richard Hess, SVP of Research and Development in BioNovelus Inc. Richard Hess worked 10+ years as President of an international water treatment company, specializing in ozone. For 20 years Richard led a bottled water company that became the second leading brand in the Philadelphia and Baltimore markets. He recently served as a senior business consultant focusing on small and middle market companies.

Frederick Taylor, BioNovelus' General Counsel, Fred Taylor has, for over thirty years, practiced law in Arizona, focusing upon service to start-ups and established businesses. His representation has included entity formation, document drafting and review, business and commercial advice, and commercial litigation.

Iain Glass, President and CEO of Mindcare Centres. Iain Glass is the founding Partner of the Mindcare Centres, a chain of medical clinics specializing in the delivery of repetitive Transcranial Magnetic Stimulation (rTMS) therapy for the treatment of depression.

His educational background in brain imaging and neuropharmacology, combined with a successful 15-year track record in hi-tech, has been instrumental in helping clear the regulatory and insurance hurdles to allow rTMS therapy in Canada. Iain Glass has been extensively involved in business analysis, development, and deployment of management and operational systems for several companies, including Imperial Oil/Exxon, Johnson & Johnson, and several e-commerce initiatives. He has also

worked extensively with Medtronic Ltd. in the development of magnetic stimulation technology.

Corporate Update

The Company is also very happy to announce the arrival of Mr. Daniel Billon-Lanfray as the SVP of Sales in Europe and the Middle East. Daniel brings to BioNovelus Inc. his 45 years of experience in the water treatment industry and in the specialty chemical space.

Daniel's expertise ranges from helping Clean Tech start-up companies to get certifications and offer brand new technologies, to assisting large corporations searching to grow their market shares through acquisitions and new contracts.

He has published reference books for engineers in English and French, including, "Treatment of Water Cooling" with Jean Claude Berce in 2005 (Springer), and "Le traitement des Eaux de refroidissement" in 2014 (Techniques de l'Ingenieur).

About BioNovelus, Inc.

BioNovelus' mission is to offer proprietary disruptive green technologies that are innovative, cost-effective solutions for our customers and partners, and that benefit our shareholders and the planet at large.

Additional Information

For additional information, please contact:

Rick Hess:
Ph. 602-888-3424
Info@BioNovelus.com

Forward-Looking Statements

Certain statements in this news release may contain forward-looking information within the meaning of Rule 175 under the Securities Act of 1933, and are subject to Rule 3B-6 under the Securities Exchange Act of 1934, and are subject to the safe harbor created by those rules. All statements, other than statements of fact, included in this press release, including, without limitation, statements regarding potential future plans and objectives of the company, are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and other results and further events could differ materially from those anticipated in such statements. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements.